Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 2436518, 7 pages
http://dx.doi.org/10.1155/2016/2436518
Research Article

TBL1XR1 Is Highly Expressed in Gastric Cancer and Predicts Poor Prognosis

1Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
3Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

Received 28 June 2016; Accepted 15 August 2016

Academic Editor: Kishore Chaudhry

Copyright © 2016 Fang Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA—A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Bertuccio, L. Chatenoud, F. Levi et al., “Recent patterns in gastric cancer: a global overview,” International Journal of Cancer, vol. 125, no. 3, pp. 666–673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. N.-Y. Hsu, K.-C. Chow, W.-J. Chen, C.-C. Lin, F.-F. Chou, and C.-L. Chen, “Expression of nm23 in the primary tumor and the metastatic regional lymph nodes of patients with gastric cardiac cancer,” Clinical Cancer Research, vol. 5, no. 7, pp. 1752–1757, 1999. View at Google Scholar · View at Scopus
  4. Y. J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar
  5. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Satoh, K. H. Lee, S. Y. Rha et al., “Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer,” Gastric Cancer, vol. 18, no. 4, pp. 824–832, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. X.-M. Zhang, Q. Chang, L. Zeng, J. Gu, S. Brown, and R. S. Basch, “TBLR1 regulates the expression of nuclear hormone receptor co-repressors,” BMC Cell Biology, vol. 7, article 31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Perissi, A. Aggarwal, C. K. Glass, D. W. Rose, and M. G. Rosenfeld, “A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors,” Cell, vol. 116, no. 4, pp. 511–526, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. E. Hoberg, F. Yeung, and M. W. Mayo, “SMRT derepression by the IκB kinase α: a prerequisite to NF-κB transcription and survival,” Molecular Cell, vol. 16, no. 2, pp. 245–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Liu, C. Lin, W. Liang et al., “TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma,” Gut, vol. 64, no. 1, pp. 26–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wang, J. Ou, Y. Guo et al., “TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer,” British Journal of Cancer, vol. 111, no. 1, pp. 112–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Li, W. Liang, J. Liu et al., “Transducin (β)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling,” Breast Cancer Research, vol. 16, article 465, 2014. View at Publisher · View at Google Scholar
  13. S.-P. Chen, Q. Yang, C.-J. Wang et al., “Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation of NF-κB pathway,” Molecular Cancer, vol. 13, no. 1, article 195, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Kuang, J. Zhu, Z. Peng, J. Wang, and Z. Chen, “Transducin (beta)-like 1 X-linked receptor 1 correlates with clinical prognosis and epithelial-mesenchymal transition in hepatocellular carcinoma,” Digestive Diseases and Sciences, vol. 61, no. 2, pp. 489–500, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. H. J. Cho, I.-K. Kim, S.-M. Park et al., “VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance,” International Journal of Cancer, vol. 135, no. 7, pp. 1553–1563, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Cao, R. Fan, W. Yang, and Y. Wu, “VEGF-C expression is associated with the poor survival in gastric cancer tissue,” Tumor Biology, vol. 35, no. 4, pp. 3377–3383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Ji, W. Ma, and W. Zheng, “Data mining of Gene expression profiles of Saccharomyces cerevisiae in response to mild heat stress response,” bioRxiv, 2014. View at Publisher · View at Google Scholar
  18. F. Liu, Q. Cao, N. Liu et al., “Overexpression of testes-specific protease 50 (TSP50) predicts poor prognosis in patients with gastric cancer,” Gastroenterology Research and Practice, vol. 2014, Article ID 498246, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Daniels, Y. Li, L. L. Gellert et al., “TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth,” Endocrine-Related Cancer, vol. 21, no. 1, pp. 127–142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Liu, W. Sun, K. Zhang et al., “Identification of genes differentially expressed in human primary lung squamous cell carcinoma,” Lung Cancer, vol. 56, no. 3, pp. 307–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Parker, Q. An, K. Barber et al., “The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1,” Genes Chromosomes and Cancer, vol. 47, no. 12, pp. 1118–1125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-T. Yan, T. Shinka, K. Kinoshita et al., “Molecular analysis of TBL1Y, a Y-linked homologue of TBL1X related with X-linked late-onset sensorineural deafness,” Journal of Human Genetics, vol. 50, no. 4, pp. 175–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. Q. An, M. Pacyna-Gengelbach, K. Schlüns et al., “Identification of differentially expressed genes in immortalized human bronchial epithelial cell line as a model for in vitro study of lung carcinogenesis,” International Journal of Cancer, vol. 103, no. 2, pp. 194–204, 2003. View at Publisher · View at Google Scholar · View at Scopus